See more : Talon 1 Acquisition Corp. (TOAC) Income Statement Analysis – Financial Results
Complete financial analysis of Pliant Therapeutics, Inc. (PLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pliant Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Kenon Holdings Ltd. (KEN) Income Statement Analysis – Financial Results
- Smiths News plc (SNWS.L) Income Statement Analysis – Financial Results
- Dolphin Capital Investors Limited (DCI.L) Income Statement Analysis – Financial Results
- Black Tusk Resources Inc. (TUSK.CN) Income Statement Analysis – Financial Results
- Sichuan Tianwei Electronic Co.,Ltd. (688511.SS) Income Statement Analysis – Financial Results
Pliant Therapeutics, Inc. (PLRX)
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.58M | 9.69M | 7.57M | 41.82M | 57.05M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 3.68M | 3.20M | 0.00 | 0.00 | 666.00K | 0.00 |
| Gross Profit | 1.58M | 6.00M | 4.37M | 41.82M | 57.05M | -666.00K | 0.00 |
| Gross Profit Ratio | 100.00% | 61.99% | 57.69% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 127.80M | 96.94M | 77.55M | 66.19M | 47.35M | 24.42M | 14.53M |
| General & Administrative | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.93M | 39.95M | 27.56M | 17.27M | 10.93M | 6.50M | 3.82M |
| Other Expenses | 0.00 | 0.00 | -77.55M | -366.00K | -216.00K | -49.00K | 0.00 |
| Operating Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Cost & Expenses | 185.73M | 136.89M | 27.56M | 83.46M | 58.28M | 30.92M | 18.35M |
| Interest Income | 24.08M | 4.67M | 272.00K | 478.00K | 816.00K | 688.00K | 16.00K |
| Interest Expense | 1.27M | 791.00K | 272.00K | 366.00K | 216.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.84M | 3.68M | 3.20M | 1.31M | 1.11M | 666.00K | 292.00K |
| EBITDA | -158.23M | -118.85M | -95.73M | -40.34M | -118.00K | -30.25M | -18.06M |
| EBITDA Ratio | -10,014.43% | -1,265.15% | -263.95% | -99.59% | -0.21% | 0.00% | 0.00% |
| Operating Income | -184.15M | -127.20M | -19.99M | -41.65M | -1.23M | -30.92M | -18.35M |
| Operating Income Ratio | -11,654.75% | -1,313.37% | -263.95% | -99.59% | -2.16% | 0.00% | 0.00% |
| Total Other Income/Expenses | 22.81M | 3.88M | 272.00K | 112.00K | 600.00K | 639.00K | 16.00K |
| Income Before Tax | -161.34M | -123.32M | -19.71M | -41.53M | -631.00K | -30.28M | -18.33M |
| Income Before Tax Ratio | -10,211.14% | -1,273.32% | -260.35% | -99.32% | -1.11% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.82M | -1.81M | -1.79M | -816.00K | 639.00K | 2.29M |
| Net Income | -161.34M | -121.50M | -17.91M | -39.75M | 185.00K | -30.28M | -20.62M |
| Net Income Ratio | -10,211.14% | -1,254.50% | -236.49% | -95.05% | 0.32% | 0.00% | 0.00% |
| EPS | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| EPS Diluted | -2.75 | -2.89 | -0.50 | -1.12 | 0.01 | -1.83 | -25.67 |
| Weighted Avg Shares Out | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
| Weighted Avg Shares Out (Dil) | 58.72M | 42.02M | 35.85M | 35.55M | 35.55M | 16.51M | 803.50K |
Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer
Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023
Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer
Pliant (PLRX) Up on Success of Mid-Stage Liver Disease Study
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?
Pliant Therapeutics' Multi-Pronged Fibrosis Play
Why Shares of Pliant Therapeutics Are Rising Tuesday
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
Source: https://incomestatements.info
Category: Stock Reports